BioStrand Omics Analysis Blog

Our omics analysis blog brings insights into genetics and genomics research solutions, and their leading role in the development of this industry.

Employee Spotlight with Carlo Wouters

BioStrand | November 24, 2022

Carlo joined Lensai (IPA) as Head of Technology in 2022, bringing with him over two decades of...

Key elements of successful AI-native drug discovery

Dr Ingrid Brands, General Manager | November 17, 2022

The use of AI in drug discovery has been progressively expanding over the past decade. Over the...

What is a biomarker?

Dr Ingrid Brands, General Manager | November 2, 2022

A biomarker, or biological marker, broadly refers to a range of objectively, accurately, and...

Precision drugs for the precision medicine era

Dr Ingrid Brands, General Manager | October 26, 2022

Currently, chemotherapy, using cytotoxic small molecules to kill cancer cells, is the predominant...

Employee Spotlight with Tom Vieijra

BioStrand | October 19, 2022

In our Employee Spotlight series, we focus on key individuals from our growing network of thought...

Subscribe to our blog

What is precision medicine?

Dr Ingrid Brands, General Manager | October 12, 2022

In 1999, an innovative collaboration between 10 of the world’s largest pharmaceutical companies,...

The role of NGS in breast cancer diagnosis and treatment

Dr Ingrid Brands, General Manager | October 6, 2022

Breast cancer is the most common cancer in women worldwide, accounting for 25% of all female...

Explained: how to plot the prediction quality metrics with AlphaFold2

Sébastien Lemal PhD | October 5, 2022

In a previous blog post, we discussed the importance of AlphaFold2 (as well as other, deep-learning...

IPA MedTech Entrepreneurship Story at TU Delft

Christophe Van Neste | September 28, 2022

My name is Christophe Van Neste, Ph. D. and I am a bioinformatician and data scientist at IPA,...

A brief retrospective on our second blogiversary

Dr Ingrid Brands, General Manager | September 21, 2022

It’s been an eventful two years, to the month, since we launched our omics and analysis blog. Our...

AI in Biopharma: Challenges and Opportunities

Dr Ingrid Brands, General Manager | September 14, 2022

There are an estimated novemdecillion, or 1060, molecules in the known universe with potential...